The "Glomerulonephritis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Glomerulonephritis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 16, 4, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.Key Topics Covered:
- Introduction
- Glomerulonephritis - Overview
- Glomerulonephritis - Therapeutics Development
- Glomerulonephritis - Therapeutics Assessment
- Glomerulonephritis - Companies Involved in Therapeutics Development
- Glomerulonephritis - Drug Profiles
- Glomerulonephritis - Dormant Projects
- Glomerulonephritis - Discontinued Products
- Glomerulonephritis - Product Development Milestones
-
Appendix
Companies Mentioned
- Achillion Pharmaceuticals Inc
- Aduro BioTech Inc
- Alexion Pharmaceuticals Inc
- Algomedix Inc
- Amyndas Pharmaceuticals LLC
- Apellis Pharmaceuticals Inc
- Aurinia Pharmaceuticals Inc
- Avexxin AS
- Biogen Inc
- Bristol-Myers Squibb Co
- Calliditas Therapeutics AB
- Cellmid Ltd
- ChemoCentryx Inc
- Complexa Inc
- Cytodesign Inc
- Dimerix Bioscience Pty Ltd
- Ergon Pharmaceuticals LLC
- Goldfinch Biopharma Inc
- HanAll Biopharma Co Ltd
- Kyowa Hakko Kirin Co Ltd
- Merck KGaA
- Novartis AG
- Omeros Corp
- Oraxion Therapeutics Inc
- Pfizer Inc
- Polyneuron Pharmaceuticals AG
- Ra Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- Retrophin Inc
- Rigel Pharmaceuticals Inc
- Sarfez Pharmaceuticals Inc
- Shire Plc
- Sujana Biotech, LLC
- Variant Pharmaceuticals Inc
- Visterra Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20180921005552/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs
